Cadrenal Therapeutics, Inc. (CVKD) Stock Statistics & Valuation Metrics

Cadrenal Therapeutics, Inc. has a market cap or net worth of $8.75M. The enterprise value is $6.58M.

Cadrenal Therapeutics, Inc. has 2,868,247 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cadrenal Therapeutics, Inc.’s return on equity (ROE) is -4.83 and return on invested capital (ROIC) is -491.51%.

The current PE Ratio of Cadrenal Therapeutics, Inc. is ―. Cadrenal Therapeutics, Inc.’s PEG ratio is 0.04.

In the last 12 months, Cadrenal Therapeutics, Inc. had revenue of 0.00 and earned -13.24M in profits. Earnings per share was -6.64.

In the last 12 months, operating cash flow was -12.60M and capital expenditures -5.10K, giving a free cash flow of -12.61M billion.

Cadrenal Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Cadrenal Therapeutics, Inc. upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).

Cadrenal Therapeutics, Inc. as a current ratio of 2.72, with Debt / Equity ratio of ―

In the past 12 months, Cadrenal Therapeutics, Inc. has paid 0.00 in taxes.

Cadrenal Therapeutics, Inc. EV to EBITDA ratio is -0.72, with an EV/FCF ratio of -0.75.

Cadrenal Therapeutics, Inc. has $4.01M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.01M billion.

Gross margin is ―, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Cadrenal Therapeutics, Inc. is $29.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy